SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy
2019 ◽
Vol 38
(6)
◽
pp. 1517-1524
◽
2013 ◽
Vol 43
(3)
◽
pp. 305-313
◽
2010 ◽
Vol 9
(9)
◽
pp. 715-734
◽